Curanex Pharmaceuticals (CURX) Q3 2025 earnings summary

Executive summary

• Completed initial public offering (IPO) on August 27, 2025, raising $13.24 million in net proceeds, with an additional $2.07 million from the over-allotment option exercised in September 2025.

• Focused on developing botanical drugs for inflammatory diseases, with Phyto-N as the lead candidate targeting seven core indications.

• No revenue generated in the quarter or year-to-date, consistent with pre-commercialization R&D stage.

• Net loss for Q3 2025 was $954,059, up from $91,166 in Q3 2024, driven by increased R&D and IPO-related expenses.

Financial highlights

• Cash and cash equivalents were $5.83 million as of September 30, 2025, up from $148,891 at December 31, 2024.

• Net loss for the nine months ended September 30, 2025, was $1,151,988, compared to $215,567 for the same period in 2024.

• R&D expenses for Q3 2025 were $677,474, reflecting IND-enabling studies; G&A expenses were $273,853.

• Prepaid R&D totaled $8.5 million as of September 30, 2025, representing advance payments to CROs and CDMOs.

• No revenue recognized; all expenses related to R&D and public company readiness.

Outlook and guidance

• Anticipates continued significant R&D spending as IND studies progress, with moderation expected until FDA approvals and clinical trials commence.

• Existing cash and IPO proceeds expected to fund operations for at least the next twelve months.

• Revenue generation expected only upon successful commercialization or strategic licensing agreements.